JBPHF (Jacobio Pharmaceuticals Group Co) EBIT per Share: $-0.02 (TTM As of Dec. 2025)


JBPHF Jacobio Pharmaceuticals Group Co Ltd JBPHF
55 GF Score
Price $0.87
GF Value $0.42
! 6 Warning Signs
View Full Analysis

What is Jacobio Pharmaceuticals Group Co EBIT per Share?

Jacobio Pharmaceuticals Group Co JBPHF +4.52% 55 EBIT per Share is $-0.02 as of Dec. 2025. GuruFocus rates JBPHF with a GF Score™ of 55/100 and a GF Value™ of $0.42. The stock has 6 warning signs investors should review. Among 1,179 Biotechnology companies, Jacobio Pharmaceuticals Group Co ranks better than 68.79% on this metric.

Jacobio Pharmaceuticals Group Co's EBIT per Share for the six months ended in Dec. 2025 was $-0.02. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.02.

During the past 3 years, the average EBIT per Share Growth Rate was 30.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Jacobio Pharmaceuticals Group Co's EBIT per Share or its related term are showing as below:

JBPHF' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -46.6   Med: -8.25   Max: 30.4
Current: 30.4

During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Jacobio Pharmaceuticals Group Co was 30.40% per year. The lowest was -46.60% per year. And the median was -8.25% per year.

JBPHF's 3-Year EBIT Growth Rate is ranked better than
68.79% of 1179 companies
in the Biotechnology industry
Industry Median: 15.6 vs JBPHF: 30.40

Jacobio Pharmaceuticals Group Co's EBIT for the six months ended in Dec. 2025 was $-11.64 Mil.

Jacobio Pharmaceuticals Group Co  (OTCPK:JBPHF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Jacobio Pharmaceuticals Group Co EBIT per Share Related Terms

Jacobio Pharmaceuticals Group Co EBIT per Share Historical Data

* Premium members only.

The historical data trend for Jacobio Pharmaceuticals Group Co's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jacobio Pharmaceuticals Group Co EBIT per Share Chart

Jacobio Pharmaceuticals Group Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT per Share
Get a 7-Day Free Trial -0.06 -0.07 -0.06 -0.03 -0.02

Jacobio Pharmaceuticals Group Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.03 0.00 -0.01 -0.02
JBPHF
55GF Score
Jacobio Pharmaceuticals Group Co Ltd JBPHF
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jacobio Pharmaceuticals Group Co EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Jacobio Pharmaceuticals Group Co's EBIT per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBIT per Share(A: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-18.89/774.511
=-0.02

Jacobio Pharmaceuticals Group Co's EBIT per Share for the quarter that ended in Dec. 2025 is calculated as

EBIT per Share(Q: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-11.638/774.916
=-0.02

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-0.02 mean?
Jacobio Pharmaceuticals Group Co (JBPHF) has a EBIT per Share of $-0.02 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. According to the industry distribution chart, Jacobio Pharmaceuticals Group Co ranks #368 out of 1179 companies in the Biotechnology industry, placing it in the top 31.2%.
Is Jacobio Pharmaceuticals Group Co's EBIT per Share too high?
Jacobio Pharmaceuticals Group Co's current EBIT per Share is $-0.02. Based on the distribution chart, Jacobio Pharmaceuticals Group Co ranks #368 out of 1179 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Jacobio Pharmaceuticals Group Co has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Jacobio Pharmaceuticals Group Co's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jacobio Pharmaceuticals Group Co ranks #368 out of 1179 companies for EBIT per Share. This puts Jacobio Pharmaceuticals Group Co in the upper half of its industry. The industry median EBIT per Share is 15.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.60, based on 1,179 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jacobio Pharmaceuticals Group Co's current EBIT per Share is $-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobio Pharmaceuticals Group Co stock overvalued right now?
Jacobio Pharmaceuticals Group Co (JBPHF) has a current EBIT per Share of $-0.02. The stock's GF Value™ is $0.42, compared to a current price of $0.87 — trading 106.6% above its estimated fair value. The current EBIT per Share is $-0.02. Jacobio Pharmaceuticals Group Co's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Jacobio Pharmaceuticals Group Co (JBPHF), the current EBIT per Share is $-0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jacobio Pharmaceuticals Group Co (JBPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co stock appears to be overvalued. The current stock price of $0.87 is trading 106.6% above its estimated GF Value™ of $0.42.

Key valuation signals for JBPHF:

  • EBIT per Share: $-0.02
  • GF Value™: $0.42 vs. price of $0.87 (106.6% above fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the JBPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jacobio Pharmaceuticals Group Co Business Description

Other Exchanges 01167:Hong Kong77V:Germany
Address No.105 Jinghai 3rd Road, Building 8, Beijing Economic-Technological Development Area, Beijing, CHN
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of oncology therapies. The company is engaged in developing breakthrough cancer therapies for patients. The producst pipeline of the company includes KRAS G12C inhibitor, SHP2 inhibitor, Pan-KRAS inhibitor, KRAS G12D ADC JAB-BX600, Aurora Kinase A (AURKA) inhibitor, BET inhibitor, P53 Y220C mutant proteins, and others.
55GF Score

Get the complete analysis for JBPHF

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.87
Price
$0.42
GF Value